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Vital in diagnosis of IHP, is contrast enhanced MRI [5, 6]. Biopsy, is the gold standard in the
setting of progressive symptoms. Microscopic findings are usually significant for densely
dispersed mixed inflammatory infiltrates, abundant lymphoplasmacytic cells, exuberant
fibroplasia, and focal hyaline degeneration [7, 8]. These biopsy findings were evident in our
patient.

Idiopathic hypertrophic pachymeningitis (IHP) is a rare disease when no other vascular
abnormality, infection, trauma, neoplasm and neuro-inflammatory condition exists. It causes
chronic inflammation with fibrosis of the cerebral and/or spinal dura mater [2].
Clinical features include headache, cranial nerve impairment, paraparesis, ataxia,
hydrocephalus, papilledema, hemorrhage, or secondary vascular occlusions [3]. Magnetic
resonance imaging (MRI) is essential for diagnosis. Most common sites of localization are
cranial (79%), spinal cord (15%), and craniospinal (5.5%) [4,1].

It has been generally accepted that first line therapy is prednisone dosed at 1 mg / kg / day.
Immunosuppressant medications are usually started if patients are refractory to the
prednisone regimen, in which azathioprine, cyclophosphamide and methotrexate are most
widely used [4, 9]. Our patient was initially started on prednisone. Azathioprine was added
shortly after generating an initial response to treatment but, the patient later had a relapse
of symptoms. Only after addition of cyclophosphamide was substantial improvement
attained. Rituximab is suggested to be a good alternative therapy for steroid-refractory
hypertrophic pachymeningitis (HP) and cases with idiopathic etiologies [11]. All patients
should be followed using ESR , C-reactive protein, and MRI [4, 9].

Case Report
51-year-old Hispanic female with diagnosis with SLE twenty years prior based on a clinical
presentation with a malar photosensitive rash, oral sores and Raynaud's disease.
In 2015 Brain MRI revealed a 1.5 x 1.5 x 0.9 cm enhancing posterior fossa mass noted as an
incidental finding and possible meningioma, however patient did not follow up on discharge.
In Early 2019, she presented to rheumatology with complaints of sharp pressure-like neck
pain, worse with lying down and extension, neck stiffness, difficulty initiating movement of
the neck, associated with numbness in her posterior neck and left upper extremity as well as
balance difficulties. MRI cervical spine revealed an extra-axial dural mass measuring 5.8 cm
in length by 1 cm anteroposterior by 2.5 cm transverse; progressively enlarged when
compared to 2015 (see Figure 1A and 2A). She had neurosurgical intervention and biopsy on
final pathologic report was positive for hypertrophic pachymeningitis. The mass showed
microscopic sections of myelofibrosis, predominantly perivascular lymphohistiocytic
inflammation with scattered plasma cells and CD20 reactive T cells and B cells. Azathioprine
50 mg daily and prednisone 60 mg tapered to 10 mg daily were started.

From initial presentation in 2019, serial immunologic testing for antibodies remained
completely negative or within normal limits.

Figure 1A

Figure 1B

One month later, MRI cervical spine showed a slightly progressive enhanced dural thickening
of the craniocervical junction extending into the cervical spine and azathioprine dose
increased to 50 mg twice daily.
4 months after, she was admitted to the hospital for stoke like symtoms and myelopathy.
Repeat MRI brain revealed the tumor to be the same size as it was in April 2019.
Azathioprine was discontinued and prednisone increased to 60mg daily.

HP many times idiopathic has been associated with various rheumatologic disorders most
notably Rheumatoid arthritis, mixed connective tissue disease, and other vasculitides (SLE,
Sjogren’s and granulomatosis with polyangiitis). This case presents a probable association
with CLE making it potentially the first reported case.

One month after stopping Azathioprine, she started cyclophosphamide 1000 mg biweekly.
in January 2020, MRI brain & C-spine respectively, showed significant improvement of about
50% in dural thickening to the posterior fossa and upper cervical cord (see Figure 1B and
Figure 2B).
Exactly one year later in early 2020, brain MRI showed no further improvement and
Cyclophosphamide discontinued. Methotrexate was considered as an alternative treatment
option; however, the patient had elevation in liver enzymes. Alternatively, rituximab was
started at induction regimen of 375 mg per metered sq. infusions once weekly for 4 weeks.
Post induction, she received two doses of 500 mg rituximab two weeks apart. Maintenance
therapy plan was for 500 to 1000 mg infusions every 16 weeks.
The presence of a photosensitive malar rash with erythema, telangiectasias affecting the
mentum, and persistence of skin lesions consisting of linear atrophic plaques with sparse
subcutaneous calcified nodules and dimpling of the skin on the forehead, buttocks, thighs,
back and arms did continue. The lesions were biopsied showing collagen vascular disease
and interface dermatitis indicative of lupus erythematosus profundus (LEP). Dermatology
suggested a deeper biopsy for further confirmation.

Our patient had characteristic dermatologic findings suggestive of LEP. LEP is a form of
cutaneous lupus erythematosus (CLE) characterized by chronic, recurrent subcutaneous
inflammatory lesions appearing as erythematous, deeply indurated, tender plaques and
nodules. CLE can present as distinct disease or in association with SLE and has a reported
incidence of 4.3 per 100,000 [12]. Patients with CLE may never progress to SLE, yet
according to population-based studies patients may demonstrate progression to SLE who
initially had CLE ranging from 0-28%. Manifestation of cutaneous disease to SLE diagnosis
can extended from months to 30 plus years [12-14]. CLE is typically divided into lupusspecific and nonspecific manifestations. Lupus-specific histopathology is distinct for lupus
including vacuolar interface dermatitis [15]. Consistent with skin biopsy in our patient. Our
patient had a presumptive diagnosis of cutaneous SLE (malar photosensitive rash,
Raynaud’s, oral sores and LEP). CLE i.e. LEP can develop into SLE, thus it is imperative to
continue to follow rheumatological markers such as ANA and dsDNA for progression to SLE.
A population based study evaluating, suggests regular lifelong screening [12].

Conclusion

Figure 2A

Figure 2B

This report demonstrates a rare incidence of IHP in possible relation to CLE. It highlights the
importance of pursuing suspicious findings on physical examination with proper imaging, lab
analysis, and surgical intervention if necessary. Despite IHP being rare, all rheumatologic
patients presenting with persistent headaches, neurologic signs, and now in conjunction
with characteristic cutaneous features, should raise suspicion for further investigation.
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